Fitness to Practise Cases
This archive contains General Pharmaceutical Council (GPhC) Fitness to Practise (FtP) case summaries, detailing regulatory decisions affecting pharmacy professionals in the UK.
Each case provides insight into professional misconduct, errors, and ethical breaches that led to sanctions such as suspension, removal, or warnings. These summaries are valuable for:
- Pharmacists & Pharmacy Technicians – to understand common regulatory pitfalls.
- Employers & HR Teams – to learn about professional accountability and compliance.
- Pharmacy Students – to prepare for real-world ethical challenges in pharmacy practice.
Why it matters:
The decisions in these cases shape the legal and ethical landscape of pharmacy practice. Staying informed can help pharmacy professionals avoid similar mistakes and maintain high professional standards.
Use the form below to search for and filter cases that match your interests
Page 7 of 50
Weight Loss Pharmacist Prescriber Suspended for Accessing Patient Phone Numbers to Initiate Sexual WhatsApp Relationships
Allegations This case concerned a pharmacist independent prescriber working remotely for IQ Doctor, an online service providing weight management treatment, including the GLP-1 receptor agonist Mounjaro (tirzepatide). As part of remote prescribing protocols, patients were required to submit photographs to support BMI verification and monitor weight-loss progress. On 29 November 2024, Patient A submitted an […]
24 February 2026
Pharmacist Suspended for Governance Breakdown in High-Volume Private Prescribing Case involving Patient Death
Allegations This case concerned a pharmacist independent prescriber and Superintendent Pharmacist who owned and operated an online pharmacy providing private prescribing services. Over a two-year period (January 2020 – December 2021), the registrant prescribed 18,683 private prescriptions through an online questionnaire-based model. The medicines included: These medicines are not benign. Several require appropriate clinical assessment, […]
NI Pharmacist Issued 3-Year Warning After Illicit Use and Supply of Sustanon (Testosterone)
Allegations This case concerned a pharmacist who admitted to the prolonged, unlawful acquisition and self-administration of testosterone, as well as the unlawful supply of Sustanon, a branded testosterone preparation. Testosterone is classified as a Prescription Only Medicine (POM) and is listed as a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations […]
23 February 2026
NI Pharmacist Struck Off After Stealing 32,000+ Pregabalin and Controlled Drugs to Fund Cocaine Addiction
Allegations This case concerned a registered pharmacist who engaged in prolonged criminal conduct involving both illicit drug use and the diversion of prescription-only medicines (POMs) and controlled drugs from her employer’s pharmacy. Between April 2015 and March 2016, while employed across three community pharmacies in Belfast (including working as a relief manager and locum pharmacist), […]
22 February 2026
Online Prescribing Under Scrutiny: Six-Month Conditions Imposed After 62,000+ Questionnaire-Based Prescriptions
Allegations This case concerned extremely high-volume online prescribing carried out by the registrant while working as a Pharmacist Independent Prescriber and later as Clinical Lead for an online provider. Over a period spanning November 2019 to July 2022, the registrant issued 62,689 prescriptions using a questionnaire-based model, including 4,859 for high-risk medicines. Of particular concern […]
20 February 2026
Extemporaneous Dispensing Errors in a Paediatric Cardiology Patient: Lessons in SOP Compliance and Professional Insight
Allegations This case concerned admitted misconduct arising from dispensing errors involving two cardiovascular medicines supplied to a highly vulnerable paediatric patient. The patient, aged two months at the time, suffered from complex congenital heart disease. The medicines involved were captopril oral solution 5 mg/ml (to be administered three times daily) and furosemide oral suspension 20 […]
19 February 2026
Pharmacist Issued Warning After Telling Patient COVID-19 Vaccine Alters DNA, Controls Us
Introduction This case concerned a pharmacist who, during a routine consultation in January 2024, expressed personal and scientifically unverified views about COVID-19 vaccination to a patient. Although no physical harm resulted, the Fitness to Practise Committee found that the registrant’s conduct amounted to serious professional misconduct. While the risk of repetition was deemed low due […]
18 February 2026
Controlled Drug Record-Keeping Failures Lead to 6-Month Suspension for NI Pharmacist
Allegations This case concerned multiple failings in the management and dispensing of Controlled Drugs and other prescription-only medicines over a period of approximately three months. The registrant, a pharmacist, faced allegations relating to Methadone, Suboxone (buprenorphine/naloxone), Diazepam, and Fentanyl patches — all medicines requiring careful clinical oversight and, in several instances, strict compliance with Controlled […]
16 February 2026
NI Pharmacist Issued Warning After Self-Supplying IVF Medicines Without Valid Prescriptions and Failing to Maintain Records
Allegations This case concerned a registered pharmacist employed as a pharmacy manager at a community pharmacy in Northern Ireland. The matter arose following a whistleblower complaint and an internal investigation by her employer, which ultimately led to her dismissal. Between August 2017 and February 2018, the registrant ordered and supplied prescription only medicines (POMs) to […]
15 February 2026
NI Pharmacist Suspended for Dishonest Falsification of 109 Prescriptions to Obtain Medicines for Wholesale Profit
Allegations This case concerned a community pharmacist who admitted to dishonestly falsifying a substantial number of prescriptions over a period of approximately four and a half months. Between August/September 2011 and January 2012, the registrant created false prescriptions in order to obtain medicines from two suppliers—Eli Lilly and Company and Healthcare at Home—for resale through […]
14 February 2026